You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Ximelagatran was non-inferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation

https://doi.org/10.1136/ebm.9.2.43

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • ↵* See glossary.

    • For correspondence: Professor S B Olsson, University Hospital, Lund, Sweden. bertil.olssonkard.lu.se

    • Source of funding: AstraZeneca.

    Linked Articles

    • Glossary
      Glossary
      BMJ Publishing Group Ltd
      BMJ Evidence-Based Medicine 2004; 9 64-64 Published Online First: 16 Apr 2004. doi: 10.1136/ebm.9.2.64